sintilimab   Click here for help

GtoPdb Ligand ID: 12990

Synonyms: IBI 308 | IBI-308 | IBI308 | Tyvyt®
Approved drug Immunopharmacology Ligand
sintilimab is an approved drug (China (2018))
Compound class: Antibody
Comment: Sintilimab (IBI 308) is a fully human IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [5]. It acts as an immune checkpoint inhibitor and is used clinically as an immuno-oncology therapeutic.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Fang X, Zhong C, Zhu N, Weng S, Hu H, Wang J, Xiao Q, Wang J, Song Y, Sun L et al.. (2022)
A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
Journal of Clinical Oncology, 40 (16_suppl): 3563. DOI: 10.1200/JCO.2022.40.16_suppl.3563
2. Hoy SM. (2019)
Sintilimab: First Global Approval.
Drugs, 79 (3): 341-346. [PMID:30742278]
3. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J et al.. (2019)
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Lancet Haematol, 6 (1): e12-e19. [PMID:30612710]
4. Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H et al.. (2023)
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
JAMA, 330 (21): 2064-2074. [PMID:38051328]
5. Zhang S, Zhang M, Wu W, Yuan Z, Tsun A, Wo M, Chen B, Li J, Miao X, Yu D et al.. (2018)
Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer.
Antibody Therapeutics, 1 (2): 65–73. DOI: 10.1093/abt/tby005